Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Nov 2026 · 1 min read
In brief
In brief
This study evaluates zoledronic acid as a therapeutic agent in four patients with metastatic osteosarcoma, demonstrating encouraging progression-free survival outcomes. The bisphosphonate shows promise through multiple mechanisms including direct anti-tumor effects, immune activation, and anti-angiogenic activity.
Written by the GCMD Library team from the article.
Statements in this article
Zoledronic acid is a third-generation bisphosphonate used to reduce pain and skeletal events in patients with bone metastases from various malignancies.
Pre-clinical studies indicate that zoledronic acid inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity.